We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTAE
151
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-250,000
Closed -$5.23M
3 4 5 6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.